Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedApr 13, 2026
DataAggregated Company Financials
Companies32
  • 7D1.0%
  • 3M-19.3%
  • 1Y-38.2%
  • YTD-18.0%

The Biotech is pretty flat in the last 7 days, but Telix Pharmaceuticals has stood out, gaining 13%. As for the longer term, the industry has declined 38% in the last year. As for the next few years, earnings are expected to grow by 31% per annum.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 13 Apr 2026AU$78.5bAU$23.3bAU$1.4b23.9x55.3x3.4x
Wed, 11 Mar 2026AU$80.8bAU$23.1bAU$1.4b25.5x57.5x3.5x
Fri, 06 Feb 2026AU$98.4bAU$23.6bAU$3.8b20.3x25.7x4.2x
Sun, 04 Jan 2026AU$95.3bAU$24.6bAU$4.0b18.5x23.8x3.9x
Tue, 02 Dec 2025AU$101.7bAU$25.1bAU$4.1b19.4x24.8x4.1x
Thu, 30 Oct 2025AU$95.6bAU$24.9bAU$4.1b18.1x23.5x3.8x
Sat, 27 Sep 2025AU$106.1bAU$25.2bAU$4.1b20.4x25.7x4.2x
Mon, 25 Aug 2025AU$117.7bAU$25.3bAU$4.2b35.9x27.8x4.7x
Wed, 23 Jul 2025AU$142.9bAU$24.4bAU$3.9b41.8x37x5.8x
Fri, 20 Jun 2025AU$129.3bAU$24.6bAU$3.9b19.9x33.2x5.3x
Sun, 18 May 2025AU$131.5bAU$24.8bAU$3.9b20.6x33.5x5.3x
Tue, 15 Apr 2025AU$129.2bAU$25.2bAU$4.0b20.2x32.5x5.1x
Thu, 13 Mar 2025AU$135.8bAU$25.3bAU$4.0b21.3x33.9x5.4x
Sat, 08 Feb 2025AU$148.1bAU$24.5bAU$3.7b24.2x40.5x6.1x
Mon, 06 Jan 2025AU$152.5bAU$24.7bAU$3.7b24.6x41.2x6.2x
Wed, 04 Dec 2024AU$151.9bAU$23.7bAU$3.5b26x43.1x6.4x
Fri, 01 Nov 2024AU$151.4bAU$23.4bAU$3.5b27.2x43.5x6.5x
Sun, 29 Sep 2024AU$149.9bAU$22.3bAU$3.3b28.1x45.6x6.7x
Tue, 27 Aug 2024AU$160.7bAU$22.8bAU$3.5b30.4x46.5x7.1x
Thu, 25 Jul 2024AU$161.4bAU$22.3bAU$3.3b32.6x49.2x7.2x
Sat, 22 Jun 2024AU$153.1bAU$22.2bAU$3.3b31.8x47.1x6.9x
Mon, 20 May 2024AU$145.0bAU$22.0bAU$3.2b31.2x45.2x6.6x
Wed, 17 Apr 2024AU$143.4bAU$22.9bAU$3.4b29.8x42.6x6.3x
Fri, 15 Mar 2024AU$144.3bAU$22.2bAU$3.2b30.4x44.5x6.5x
Sun, 11 Feb 2024AU$154.9bAU$21.0bAU$2.9b35x54.2x7.4x
Tue, 09 Jan 2024AU$145.6bAU$20.5bAU$2.7b33.9x53.6x7.1x
Thu, 07 Dec 2023AU$136.2bAU$20.9bAU$2.8b33.7x49.2x6.5x
Sat, 04 Nov 2023AU$124.1bAU$21.3bAU$2.8b29.8x43.7x5.8x
Mon, 02 Oct 2023AU$128.6bAU$21.4bAU$2.8b29.6x45.9x6x
Wed, 30 Aug 2023AU$136.7bAU$21.4bAU$2.6b35.1x52.6x6.4x
Fri, 28 Jul 2023AU$138.4bAU$17.7bAU$2.3b38.2x60.8x7.8x
Sun, 25 Jun 2023AU$145.0bAU$18.0bAU$2.3b37.8x62.4x8.1x
Tue, 23 May 2023AU$156.0bAU$18.1bAU$2.3b40.5x66.8x8.6x
Thu, 20 Apr 2023AU$153.3bAU$17.9bAU$2.3b41.9x66.3x8.5x
Price to Earnings Ratio

66.3x


Total Market Cap: AU$153.3bTotal Earnings: AU$2.3bTotal Revenue: AU$17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 43.3x202420252026
Current Industry PE
  • Investors are optimistic on the Australian Biotechs industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 55.3x which is higher than its 3-year average PE of 43.3x.
  • The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have declined 15% per year over the last three years.
  • Meanwhile revenues for these companies have grown 9.3% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Australian Healthcare industry?

AU Market4.32%
Healthcare1.46%
Biotech0.95%
Biotech0.95%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TLX Telix PharmaceuticalsAU$14.6413.1%
+AU$572.7m		-44.1%PS4.4x
CSL CSLAU$139.190.2%
+AU$112.2m		-40.3%PE33.9x
PYC PYC TherapeuticsAU$1.185.4%
+AU$59.0m		19.9%PS56.2x
TTX TetratherixAU$4.9413.8%
+AU$30.5m		n/aPS125.5x
RAC Racura OncologyAU$2.754.6%
+AU$21.9m		169.6%PS144.2x

Latest News

TLX
AU$14.64
Telix Pharmaceuticals
7D
13.1%
1Y
-44.1%
CSL
AU$139.19
CSL
7D
0.2%
1Y
-40.3%

CSL: Manufacturing Expansion And CEO Transition Will Support Future Share Recovery

Analysts have slightly increased CSL's fair value estimate to A$208.11, citing modest adjustments to the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple as they reassess the stock following recent rating changes. Analyst Commentary Recent rating actions around CSL highlight a split in views on how much investors should pay for the stock at this stage, which feeds directly into the updated fair value estimate of A$208.11.
ARX
AU$0.53
Aroa Biosurgery
7D
-8.6%
1Y
35.9%

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
RAC
AU$2.75
Racura Oncology
7D
4.6%
1Y
169.6%
ATX
AU$0.15
Amplia Therapeutics
7D
-35.4%
1Y
198.1%

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Mar 31
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
PYC
AU$1.18
PYC Therapeutics
7D
5.4%
1Y
19.9%
IMM
AU$0.04
Immutep
7D
-9.1%
1Y
-83.3%
TTX
AU$4.94
Tetratherix
7D
13.8%
1Y
n/a
MSB
AU$2.12
Mesoblast
7D
-0.5%
1Y
34.6%
IMU
AU$0.14
Imugene
7D
-3.4%
1Y
-82.8%
PAR
AU$0.23
Paradigm Biopharmaceuticals
7D
-11.5%
1Y
-20.7%
DXB
AU$0.34
Dimerix
7D
6.3%
1Y
-13.9%
NXN
AU$0.18
Nexsen
7D
-5.1%
1Y
n/a
BDX
AU$0.092
BCAL Diagnostics
7D
-7.1%
1Y
3.4%
PTX
AU$0.056
Prescient Therapeutics
7D
7.7%
1Y
33.3%
COV
AU$0.58
Cleo Diagnostics
7D
5.4%
1Y
56.0%